

NCCN and Other Leading Cancer Organizations Issue Consensus Statement on U.S. Drug Shortages, Urge Policy Action

The statement urges Congress to increase supply chain transparency, strengthen manufacturer incentives, and stabilize generic drug markets.

May 21, 2026 By National Comprehensive Cancer Network

PLYMOUTH MEETING, PA [Wednesday, May 13, 2026]—Today, the National Comprehensive Cancer Network® (NCCN®), in collaboration with other organizations across the cancer community, released a [consensus statement](#) identifying the primary drivers of the persistent drug shortage crisis in the United States and proposing actionable policy solutions to protect access to critical cancer medications.

The statement outlines three priorities that require immediate action to address both the root causes and patient impact of drug shortages:

- Increasing transparency across the drug supply chain
- Strengthening incentives for manufacturers to invest in high-quality, redundant supply systems
- Stabilizing the generic drug market

Read the full statement at [NCCN.org/drug-shortages](https://www.nccn.org/drug-shortages).

Cancer drug shortages continue to pose a serious challenge to delivering safe, timely, and effective care. Over the past five years, hundreds of thousands of cancer patients have experienced disruptions to their treatment plans due to ongoing shortages, often resulting in suboptimal care and outcomes. At the same time, healthcare providers have devoted substantial time and resources to managing these shortages, diverting attention from direct patient care.

This crisis requires comprehensive and coordinated action. Pharmaceutical manufacturers,

healthcare providers, and government stakeholders must work together to find sustainable solutions. We urge Congress and the Administration to prioritize targeted policy interventions that address supply chain vulnerabilities and promote a more resilient and reliable drug supply.

The organizations who have issued this statement collectively represent thousands of patients, caregivers, and healthcare professionals nationwide. Together, we are committed to advancing practical, sustainable solutions that ensure a stable supply of essential cancer medications. Ensuring that no patient faces uncertainty regarding the availability of life-saving treatments remains our highest priority.

Learn more at [NCCN.org/drug-shortages](https://www.nccn.org/drug-shortages).

SIGNATORIES:

- Hematology/Oncology Pharmacy Association (HOPA) American Society of Hematology (ASH)
- American Society of Pediatric Hematology/Oncology (ASPHO) The Andrew McDonough B+ Foundation
- Association of American Cancer Institutes (AACI) Association of Cancer Care Centers (ACCC)
- Association of Pediatric Hematology/Oncology Nurses (APHON) Children's Brain Tumor Foundation
- Children's Cancer Research Fund Community Oncology Alliance (COA) KidneyCAN
- Myeloma Research Foundation
- National Comprehensive Cancer Network® (NCCN®)
- Network for Collaborative Oncology Development & Advancement (NCODA) MIB Agents Osteosarcoma
- Oncology Nursing Society (ONS)
- Ovarian Cancer Research Alliance (OCRA) Society for Gynecologic Oncology (SGO)

[This announcement](#) was originally published May 13, 2026, on the [National Comprehensive Cancer Network website](#).